Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Unknown 1Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 4Biliary Tract Neoplasms 3Neoplasms 2Klatskin Tumor 2Esophageal Neoplasms 2Jaundice, Obstructive 1Gastric Outlet Obstruction 1

Interventions

Gemcitabine 91Cisplatin 69Oxaliplatin 37Capecitabine 37durvalumab 29Fluorouracil 26pembrolizumab 24Leucovorin 22S 1 (combination) 18Nivolumab 13Irinotecan 13lenvatinib 12Bevacizumab 11tremelimumab 10apatinib 8Trastuzumab 7Injections 7Albumin-Bound Paclitaxel 7130-nm albumin-bound paclitaxel 7Paclitaxel 6Immune Checkpoint Inhibitors 6Docetaxel 6titanium silicide 5surufatinib 5envafolimab 5camrelizumab 5atezolizumab 5Folfox protocol 5Drug Therapy 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Biliary Tract Neoplasms × Self Expandable Metallic Stents × Clear all
NCT06653192 2026-05-06

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)

Hospital Universitari de Bellvitge

Phase NA Suspended
120 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

NCT06375928 2024-04-19

EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction in Resectable Disease (CARPEDIEM-1 Trial)

Hospital Universitari de Bellvitge

Phase NA Unknown
44 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT06375954 2024-04-19

EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial)

Hospital Universitari de Bellvitge

Phase NA Not yet recruiting
96 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡